drugset / Trial / NCT06929156

A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

NCT06929156

Phase 1 Completed 34 enrolled BrightGene Bio-Medical Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Timeline

Start
2025-05-06
Primary completion
2025-12-25
Completion
2025-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown